Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKI) for optimized outcome in patients with metastatic renal cell carcinoma. The TKI-TDM Trial. Study protocol
Identifying plasma TKI levels associated with efficacy and reduced toxicity could minimize under- or overdosing, improving outcomes and quality of life. TDM may allow dose adjustments early in therapy, improving therapeutic management and reducing healthcare costs. Findings may also inform treatment of other cancers using TKIs or TKI-immunotherapy combinations. The trial (clinicaltrials.gov NCT04659343) is expected to conclude in 2028, with results in 2029.
Authors
- Niels Fristrup (ORCID: https://orcid.org/0009-0006-4442-0535)
- Eva Greibe (ORCID: https://orcid.org/0000-0002-0417-1195)
- Frede Donskov (ORCID: https://orcid.org/0000-0002-8449-863X)
- Charlotte Uggerhøj Andersen (ORCID: https://orcid.org/0000-0003-0543-6519)
- Elke Hoffmann (ORCID: https://orcid.org/0000-0002-2437-0140)
- Jakob Nørgaard Henriksen (ORCID: https://orcid.org/0000-0003-0784-3206)
Institutions
- University of Southern Denmark (DK)
- Aarhus University Hospital (DK)
- Region of Southern Denmark (DK)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2025-06-02
- DOI
- https://doi.org/10.2340/1651-226x.2025.43693
- Citations
- 2
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04